Clinical Trial Update: Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer [Phase 2]

View source ↗

Summary

Phase II study of docetaxel plus celecoxib in patients with androgen-independent (metastatic) prostate cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Celecoxib (Celecoxib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sanofi | Conditions: Metastatic Prostate Cancer | Phase 2 | Status: TERMINATED